|Mr. Pascal Soriot D.V.M., M.B.A.||CEO & Exec. Director||4.39M||N/A||1959|
|Mr. Marc Dunoyer||Chief Exec. Officer of Alexion||2.45M||N/A||1952|
|Dr. Aradhana Sarin M.D.||CFO & Exec. Director||N/A||N/A||1975|
|Ms. Pam P. Cheng||EVP of Operations & Information Technology and Member of External Sustainability Advisory Board||N/A||N/A||1971|
|Mr. Thomas Kudsk Larsen||Head of Investor Relations||N/A||N/A||1974|
|Mr. Jeffrey Pott||EVP of HR, Chief HR Officer, Gen. Counsel & Member of External Sustainability Advisory Board||N/A||N/A||N/A|
|Ms. Katarina Ageborg||EVP of Sustainability, Chief Compliance Officer & Member of External Sustainability Advisory Board||N/A||N/A||N/A|
|Dr. Menelas Pangalos Ph.D.||EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board||N/A||N/A||N/A|
|Dr. Ruud Dobber Ph.D.||Exec. Vice-Pres of BioPharmaceuticals Bus. Unit||N/A||N/A||N/A|
|Dr. Susan Mary Galbraith M.D., Ph.D.||Exec. VP of Oncology R&D||N/A||N/A||1966|
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; Proteros biostructures GmbH to discover and develop novel small molecules. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; and Scorpion Therapeutics, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. The company was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
AstraZeneca PLC’s ISS governance QualityScore as of 26 September 2021 is 7. The pillar scores are Audit: 1; Board: 9; Shareholder rights: 1; Compensation: 7.